Spots Global Cancer Trial Database for Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women
Official Title: PREDICT TRIAL- Neoadjuvant Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women Expressing Hormonal Receptors ( ER and PR)
Study ID: NCT00237133
Conditions
Interventions
Study Description
Brief Summary: Open-label Phase IV trial of Letrozole 2,5mg po/day for 120 days prior to surgery for patients with locally advanced breast in postmenopausal women expressing hormonal receptors ( ER and PR)
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Novartis Investigative Site, Barretos - SP, , Brazil
Novartis Investigative Site, Florianopolis - SC, , Brazil
Novartis Investigative Site, Fortaleza/CE, , Brazil
Novartis Investigative Site, Goiania/GO, , Brazil
Novartis Investigative Site, Jau -SP, , Brazil
Novartis Investigative Site, Porto Alegre/RS, , Brazil
Novartis Investigative Site, Ribeirao - SP, , Brazil
Novartis Investigative Site, Rio de Janeiro, , Brazil
Novartis Investigative Site, Santo Andre, , Brazil
Novartis Investigative Site, Sao Paulo/SP, , Brazil
Novartis Investigative Site, Vitoria/ES, , Brazil
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
